Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Elacestrant (Orserdu) is a hormonal therapy used to treat metastatic breast cancer.

Read More

 | 5 Min. Read |  1

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with metastatic, triple-negative breast cancer and people diagnosed with metastatic breast cancer that is hormone receptor-positive and HER2-negative.

Read More

 | 5 Min. Read |  7

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal therapy is a type of targeted therapy because it targets hormones that are active in cancer growth.

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 5 Min. Read |  3

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 6 Min. Read |  1

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

If you are diagnosed with HER2-positive breast cancer, you may be wondering what that means. Read about the ins-and-outs of HER2-positive breast cancer.

Read More

 | 14 Min. Read |  7

Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones occur naturally in the body and prompt cell action in different ways.

Read More

 | 15 Min. Read |  2

Neratinib (Nerlynx) is a targeted therapy for people with HER2-positive breast cancer. It is the first medicine for people with HER2-positive breast cancer approved as extended therapy, meaning that for early-stage disease, it is given after primary treatment ends to lower the risk of cancer coming back.